The Encephalopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Encephalopathy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Encephalopathy Market.
Some of the key takeaways from the Encephalopathy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Encephalopathy treatment therapies with a considerable amount of success over the years.
- Encephalopathy companies working in the treatment market are CAMP4 Therapeutics, LifeSplice, Encoded Therapeutics, CuroNZ, Cerecin, Longboard Pharmaceuticals, Neurocrine Biosciences, Vedanta Biosciences, PTC Therapeutics, Xenon Pharmaceuticals Inc., Amzell, Axcella Health, Rebiotix, Stoke Therapeutics, Longboard Pharma, Knopp Bioscience, and others, are developing therapies for the Encephalopathy treatment
- Emerging Encephalopathy therapies in the different phases of clinical trials are- MP-SCN, SP-SCN8, ETX101, NRP 2945, Tricaprilin, LP352, NBI-921352, VE303, Vatiquinone, XEN496, AMZ 002, AXA 1665, RBX 7455, STK-001, LP352, KB-3061, and others are expected to have a significant impact on the Encephalopathy market in the coming years.
- In August 2023, In a Phase II clinical trial using the medicine RLS-0071 to treat newborns with hypoxic-ischemic encephalopathy (HIE), also known as birth asphyxia, ReAlta Life Sciences has dosed the first patient.
- In June 2022, ReAlta Life Sciences said that RLS-0071 has been given Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of hypoxia ischemic encephalopathy (HIE). The leading dual action complement inhibitor and innate anti-inflammatory peptide for the company is RLS-0071. RLS-0071's Phase II clinical trial application for approval by the US FDA was submitted in March 2022.
- The lead MRT drug platform product RBX2660 is intended to treat multi-drug resistant pathogens, ulcerative colitis, Clostridium difficile (C.diff), and hepatic encephalopathy. Rebiotix has received U.S. Patent No. 9,433,651 from the United States Patent and Trademark Office (USPTO) in relation to its patent application titled "Microbiota Restoration Therapy (MRT), Compositions and Methods of Manufacture." The invention expands upon Rebiotix's patent issuances in Australia and Canada and covers Microbiota Restoration Therapy (MRT) formulations and methods for producing, processing, and administering the compositions.
- The first preferred persistent sodium channel blocker, PRAX-562, is being developed to treat a variety of uncommon CNS conditions, such as rare adult cephalgias, developmental, and epileptic encephalopathies. The US FDA designated PRAX-562 as an orphan drug in April 2021 for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) and as a rare paediatric disease in January 2021 for the treatment of SCN2A-DEE and SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
- In August 2021, A non-exclusive strategic partnership between Vyant Bio, Inc. and Cyclica, Inc. has been announced. It will combine the companies' patient-derived complex organoid biology and proteome-wide AI-enabled discovery platforms to find new treatments for CDKL5 Deficiency Disorder ("CDD"), a severe neurodevelopmental epilepsy disorder that currently has no effective treatments or cure.
Encephalopathy Overview
The term "encephalopathy" denotes a condition that affects the brain. The phrase describes both short- and long-term conditions that have an impact on the structure or operation of the brain. Encephalopathy comes in two basic varieties: reversible and irreversible.
Get a Free Sample PDF Report to know more about Encephalopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/encephalopathy-pipeline-insight
Emerging Encephalopathy Drugs Under Different Phases of Clinical Development Include:
- MP-SCN: CAMP4 Therapeutics
- SP-SCN8: LifeSplice
- ETX101: Encoded Therapeutics
- NRP 2945: CuroNZ
- Tricaprilin: Cerecin
- LP352: Longboard Pharmaceuticals
- NBI-921352: Neurocrine Biosciences
- VE303: Vedanta Biosciences
- Vatiquinone: PTC Therapeutics
- XEN496: Xenon Pharmaceuticals Inc.
- AMZ 002: Amzell
- AXA 1665: Axcella Health
- RBX 7455: Rebiotix
- STK-001: Stoke Therapeutics
- LP352: Longboard Pharma
- KB-3061: Knopp Bioscience
Encephalopathy Route of Administration
Encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Encephalopathy Molecule Type
Encephalopathy Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Encephalopathy Pipeline Therapeutics Assessment
- Encephalopathy Assessment by Product Type
- Encephalopathy By Stage and Product Type
- Encephalopathy Assessment by Route of Administration
- Encephalopathy By Stage and Route of Administration
- Encephalopathy Assessment by Molecule Type
- Encephalopathy by Stage and Molecule Type
DelveInsight's Encephalopathy Report covers around 70+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Encephalopathy product details are provided in the report. Download the Encephalopathy pipeline report to learn more about the emerging Encephalopathy therapies
Some of the key companies in the Encephalopathy Therapeutics Market include:
Key companies developing therapies for Encephalopathy are - Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, SK Biopharmaceutical, Epygenix Therapeutics, Jazz Pharmaceuticals, Vedanta Biosciences, Versantis, ReAlta Life Sciences, Cosmo Pharmaceuticals, Pharmazz, Umecrine Cognition AB, Neuropathix, DeckTherapeutics, Vittarthaa Life Sciences, Tetra Therapeutics, AC Immune, Brighton Biotech Inc., JCR Pharmaceuticals, Vyant Bio, Inc., Encoded therapeutics, Incannex, Amzell, Bio Pharm Solutions, Anavex Life Sciences, and others.
Encephalopathy Pipeline Analysis:
The Encephalopathy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Encephalopathy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Encephalopathy Treatment.
- Encephalopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Encephalopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Encephalopathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Encephalopathy drugs and therapies
Encephalopathy Pipeline Market Drivers
- Increasing research & Development activities, continuous development of technology offering therapies for the treatment of various complications are some of the important factors that are fueling the Encephalopathy Market.
Encephalopathy Pipeline Market Barriers
- However, high cost of treatment, poor diagnosis in terms of the type of Encephalopathy and other factors are creating obstacles in the Encephalopathy Market growth.
Scope of Encephalopathy Pipeline Drug Insight
- Coverage: Global
- Key Encephalopathy Companies: CAMP4 Therapeutics, LifeSplice, Encoded Therapeutics, CuroNZ, Cerecin, Longboard Pharmaceuticals, Neurocrine Biosciences, Vedanta Biosciences, PTC Therapeutics, Xenon Pharmaceuticals Inc., Amzell, Axcella Health, Rebiotix, Stoke Therapeutics, Longboard Pharma, Knopp Bioscience, and others
- Key Encephalopathy Therapies: MP-SCN, SP-SCN8, ETX101, NRP 2945, Tricaprilin, LP352, NBI-921352, VE303, Vatiquinone, XEN496, AMZ 002, AXA 1665, RBX 7455, STK-001, LP352, KB-3061, and others
- Encephalopathy Therapeutic Assessment: Encephalopathy current marketed and Encephalopathy emerging therapies
- Encephalopathy Market Dynamics: Encephalopathy market drivers and Encephalopathy market barriers
Request for Sample PDF Report for Encephalopathy Pipeline Assessment and clinical trials
Table of Contents
1. Encephalopathy Report Introduction
2. Encephalopathy Executive Summary
3. Encephalopathy Overview
4. Encephalopathy- Analytical Perspective In-depth Commercial Assessment
5. Encephalopathy Pipeline Therapeutics
6. Encephalopathy Late Stage Products (Phase II/III)
7. Encephalopathy Mid Stage Products (Phase II)
8. Encephalopathy Early Stage Products (Phase I)
9. Encephalopathy Preclinical Stage Products
10. Encephalopathy Therapeutics Assessment
11. Encephalopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Encephalopathy Key Companies
14. Encephalopathy Key Products
15. Encephalopathy Unmet Needs
16 . Encephalopathy Market Drivers and Barriers
17. Encephalopathy Future Perspectives and Conclusion
18. Encephalopathy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
